

(70312)

Medical Benefit		Effective Date: 07/01/15	Next Review Date: 05/19
Preauthorization	Yes	Review Dates: 05/09, 05/10, 05/11, 05/12, 05/13, 05/14, 05/15, 05/16, 05/17, 05/18	

Preauthorization is required and must be obtained through Case Management.

The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient's contract at the time the services are rendered.

Populations	Interventions	Comparators	Outcomes
Individuals: <ul style="list-style-type: none"> • With chronic pancreatitis undergoing total or near total pancreatectomy 	Interventions of interest are: <ul style="list-style-type: none"> • Autologous pancreas islet transplantation 	Comparators of interest are: <ul style="list-style-type: none"> • Standard clinical management 	Relevant outcomes include: <ul style="list-style-type: none"> • Overall survival • Change in disease status • Medication use • Resource utilization • Treatment-related morbidity
Individuals: <ul style="list-style-type: none"> • With type 1 diabetes 	Interventions of interest are: <ul style="list-style-type: none"> • Allogeneic pancreas islet transplantation 	Comparators of interest are: <ul style="list-style-type: none"> • Standard clinical management 	Relevant outcomes include: <ul style="list-style-type: none"> • Overall survival • Change in disease status • Medication use • Resource utilization • Treatment-related morbidity

DESCRIPTION

Performed in conjunction with pancreatectomy, autologous islet transplantation is proposed to reduce the likelihood of insulin-dependent diabetes. Moreover, allogeneic islet cell transplantation is being investigated as a treatment or cure for patients with type 1 diabetes.

SUMMARY OF EVIDENCE

For individuals with chronic pancreatitis undergoing total or near total pancreatectomy who receive autologous pancreas islet transplantation, the evidence includes case series and systematic reviews. Relevant outcomes are overall survival, change in disease status, medication use, resource utilization, and treatment-related morbidity. Autologous islet transplants are performed in the context of total or near total pancreatectomies to treat intractable pain for chronic pancreatitis. The procedure appears to significantly decrease the incidence of diabetes after total or near total pancreatectomy in patients with chronic pancreatitis. Also, this procedure itself is not associated with serious complications and is performed in patients who are already undergoing a pancreatectomy procedure. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals with type 1 diabetes who receive allogeneic pancreas islet transplantation, the evidence includes case series and systematic reviews. Relevant outcomes are overall survival, change in disease status, medication use, resource utilization, and treatment-related morbidity. A wide range of insulin independence has been reported in case series. There is conflicting evidence whether allogeneic islet transplantation reduces long-term diabetic complications. Long-term comparative studies are required to determine the effects of allogeneic islet transplantation in type 1 diabetics. The evidence is insufficient to determine the effects of the technology on health outcomes.

POLICY

Autologous pancreas islet transplantation may be considered **medically necessary** as an adjunct to a total or near total pancreatectomy in patients with chronic pancreatitis.

Allogeneic islet transplantation is considered **investigational** for the treatment of type 1 diabetes.

Islet transplantation is considered **investigational** in all other situations.

POLICY GUIDELINES

Individual transplant facilities may have their own additional requirements or protocols that must be met in order for the patient to be eligible for a transplant at their facility.

MEDICARE ADVANTAGE

Coverage may only be available through Original Medicare for pancreatic islet cell transplantation for Medicare Advantage members participating in a National Institutes of Health (NIH) sponsored clinical trial(s). If a transplant is needed, we arrange to have the Medicare-approved transplant center review and decide whether the patient is an appropriate candidate for the transplant.

BACKGROUND

ISLET TRANSPLANTATION

In autologous islet transplantation during the pancreatectomy procedure, islet cells are isolated from the resected pancreas using enzymes, and a suspension of the cells is injected into the portal vein of the patient's liver. Once implanted, the beta cells in these islets begin to make and release insulin.

In the case of allogeneic islet cell transplantation, cells are harvested from a deceased donor's pancreas, processed, and injected into the recipient's portal vein. Up to three donor pancreas transplants may be required to achieve insulin independence. Allogeneic transplantation may be performed in the radiology department.

CHRONIC PANCREATITIS

Primary risk factors for chronic pancreatitis include toxic-metabolic, idiopathic, genetic, autoimmune, recurrent and severe acute, or obstructive (TIGAR-O classification system). Patients with chronic pancreatitis may experience intractable pain that can only be relieved with a total or near total pancreatectomy. However, the pain relief must be balanced against the certainty that the patient will be rendered an insulin-dependent diabetic.

TYPE 1 DIABETES

Allogeneic islet transplantation has been used for type 1 diabetes to restore normoglycemia and, ultimately, to reduce or eliminate the long-term complications of diabetes such as retinopathy, neuropathy, nephropathy, and

cardiovascular disease. Islet transplantation potentially offers an alternative to whole-organ pancreas transplantation. However, a limitation of islet transplantation is that two or more donor organs are usually required for successful transplantation, although experimentation with single-donor transplantation is occurring. A pancreas that is rejected for whole-organ transplant is typically used for islet transplantation. Therefore, islet transplantation has generally been reserved for patients with frequent and severe metabolic complications who have consistently failed to achieve control with insulin-based management.

In 2000, a modified immunosuppression regimen increased the success of allogeneic islet transplantation. This regimen was developed in Edmonton, AB, Canada, and is known as the “Edmonton protocol.”

REGULATORY STATUS

The U.S. Food and Drug Administration regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation title 21, parts 1270 and 1271. Allogeneic islet cells are included in these regulations.

RELATED PROTOCOL

Allogeneic Pancreas Transplant

Services that are the subject of a clinical trial do not meet our Technology Assessment Protocol criteria and are considered investigational. *For explanation of experimental and investigational, please refer to the Technology Assessment Protocol.*

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. **Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.**

REFERENCES

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.

1. Wu Q, Zhang M, Qin Y, et al. Systematic review and meta-analysis of islet autotransplantation after total pancreatectomy in chronic pancreatitis patients. *Endocr J.* Mar 30 2015; 62(3):227-234. PMID 25735805
2. Dong M, Parsaik AK, Erwin PJ, et al. Systematic review and meta-analysis: islet autotransplantation after pancreatectomy for minimizing diabetes. *Clin Endocrinol (Oxf).* Dec 2011; 75(6):771-779. PMID 21605156
3. Wilson GC, Sutton JM, Abbott DE, et al. Long-term outcomes after total pancreatectomy and islet cell autotransplantation: is it a durable operation? *Ann Surg.* Oct 2014; 260(4):659-665; discussion 665-657. PMID 25203883
4. Chinnakotla S, Radosevich DM, Dunn TB, et al. Long-term outcomes of total pancreatectomy and islet auto transplantation for hereditary/genetic pancreatitis. *J Am Coll Surg.* Apr 2014; 218(4):530-543. PMID 24655839
5. Sutherland DE, Radosevich DM, Bellin MD, et al. Total pancreatectomy and islet autotransplantation for chronic pancreatitis. *J Am Coll Surg.* Apr 2012; 214(4):409-424. PMID 22397977

6. Food and Drug Administration (FDA). Guidance for Industry: Considerations for Allogeneic Pancreatic Islet Cell Products. 2009; <http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM182441.pdf>. Accessed August 14, 2017.
7. Piper M, Seidenfeld J, Aronson N. Islet transplantation in patients with type 1 diabetes mellitus. *Evid Rep Technol Assess (Summ)*. Jul 2004(98):1-6. PMID 15366369
8. Alejandro R, Barton FB, Hering BJ, et al. 2008 Update from the Collaborative Islet Transplant Registry. *Transplantation*. Dec 27 2008; 86(12):1783-1788. PMID 19104422
9. Barton FB, Rickels MR, Alejandro R, et al. Improvement in outcomes of clinical islet transplantation: 1999-2010. *Diabetes Care*. Jul 2012; 35(7):1436-1445. PMID 22723582
10. Thompson DM, Meloche M, Ao Z, et al. Reduced progression of diabetic microvascular complications with islet cell transplantation compared with intensive medical therapy. *Transplantation*. Feb 15 2011; 91(3):373-378. PMID 21258272
11. Caiazzo R, Vantighem MC, Raverdi V, et al. Impact of procedure-related complications on long-term islet transplantation outcome. *Transplantation*. May 2015; 99(5):979-984. PMID 25393157
12. O'Connell PJ, Holmes-Walker DJ, Goodman D, et al. Multicenter Australian trial of islet transplantation: improving accessibility and outcomes. *Am J Transplant*. Jul 2013; 13(7):1850-1858. PMID 23668890
13. Rickels MR, Kong SM, Fuller C, et al. Improvement in insulin sensitivity after human islet transplantation for type 1 diabetes. *J Clin Endocrinol Metab*. Nov 2013; 98(11):E1780-1785. PMID 24085506
14. Health Quality Ontario. Pancreas islet transplantation for patients with type 1 diabetes mellitus: a clinical evidence review. *Ont Health Technol Assess Ser*. 2015; 15(16):1-84. PMID 26644812
15. National Institute for Health and Care Excellence (NICE). Allogenic pancreatic islet cell transplantation for type 1 diabetes mellitus [IPG257]. 2008; <http://www.nice.org.uk/Guidance/IPG257>. Accessed August 14, 2017.
16. National Institute for Health and Care Excellence (NICE). Autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy [IPG274]. 2008; <http://www.nice.org.uk/Guidance/IPG274>. Accessed August 14, 2017.
17. Centers for Medicare and Medicaid. National Coverage Determination (NCD) for ISLET CELL Transplantation in the Context of a Clinical Trial (260.3.1). 2004; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=286&ncdver=1&CoverageSelection=Both&ArticleType=All&PolicyType=Final&s=All&Keyword=islet+cell&KeywordLookup=Title&KeywordSearchType=And&bc=gAAAABAAAA&>. Accessed August 4, 2017.